A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (Rituximab, Roche) in Indian patients of non-hodgkin's lymphoma (HERILY)
Objective: To compare the antitumor efficacy, safety, and pharmacodynamic (PD) characteristics of Hetero-rituximab (test) with reference medicinal product (rituximab, Roche) in non-Hodgkin's lymphoma. Patients and Methods: One hundred and thirty-five patients with diffuse large B-cell lymphoma...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2018-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2018;volume=39;issue=3;spage=316;epage=320;aulast=Advani |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849768001927118848 |
|---|---|
| author | Suresh Advani Ghanashyam Biswas Shubhadeep Sinha Neetu Naidu Rayala Sreenivasa Chary Pankaj Thakur Anushrita Santanu Tripathi Vamsi Krishna Bandi |
| author_facet | Suresh Advani Ghanashyam Biswas Shubhadeep Sinha Neetu Naidu Rayala Sreenivasa Chary Pankaj Thakur Anushrita Santanu Tripathi Vamsi Krishna Bandi |
| author_sort | Suresh Advani |
| collection | DOAJ |
| description | Objective: To compare the antitumor efficacy, safety, and pharmacodynamic (PD) characteristics of Hetero-rituximab (test) with reference medicinal product (rituximab, Roche) in non-Hodgkin's lymphoma. Patients and Methods: One hundred and thirty-five patients with diffuse large B-cell lymphoma (DLBCL) were randomized to receive intravenous infusion of either test or reference product. Efficacy (best overall response [BOR] rate [primary end point]), safety, PD (CD19), and immunological assessments (secondary end points) were done at the end of cycle 3 and cycle 6. Results: At the end of 6 cycles, BOR rate was 73.47% in Hetero-rituximab test arm compared to the 69.09% in reference arm. Anti-rituximab antibodies were found to be negative at cycle 3 and cycle 6 for all patients. Patients treated with Hetero-rituximab show a significant depletion in CD19+ cell which was comparable with reference drug. Safety and immunogenic potential of the test drug was comparable to the reference drug in the patients of DLBCL. Conclusion: BOR rate at cycle 3, cycle 6, and end of the study lies within the prespecified limit for noninferiority which concludes that test product is therapeutically noninferior to reference medicinal product. |
| format | Article |
| id | doaj-art-a688fa2a19704e16a6c2f6d7b4bd66ca |
| institution | DOAJ |
| issn | 0971-5851 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-a688fa2a19704e16a6c2f6d7b4bd66ca2025-08-20T03:03:59ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58512018-01-0139331632010.4103/ijmpo.ijmpo_25_17A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (Rituximab, Roche) in Indian patients of non-hodgkin's lymphoma (HERILY)Suresh AdvaniGhanashyam BiswasShubhadeep SinhaNeetu Naidu RayalaSreenivasa CharyPankaj ThakurAnushritaSantanu TripathiVamsi Krishna BandiObjective: To compare the antitumor efficacy, safety, and pharmacodynamic (PD) characteristics of Hetero-rituximab (test) with reference medicinal product (rituximab, Roche) in non-Hodgkin's lymphoma. Patients and Methods: One hundred and thirty-five patients with diffuse large B-cell lymphoma (DLBCL) were randomized to receive intravenous infusion of either test or reference product. Efficacy (best overall response [BOR] rate [primary end point]), safety, PD (CD19), and immunological assessments (secondary end points) were done at the end of cycle 3 and cycle 6. Results: At the end of 6 cycles, BOR rate was 73.47% in Hetero-rituximab test arm compared to the 69.09% in reference arm. Anti-rituximab antibodies were found to be negative at cycle 3 and cycle 6 for all patients. Patients treated with Hetero-rituximab show a significant depletion in CD19+ cell which was comparable with reference drug. Safety and immunogenic potential of the test drug was comparable to the reference drug in the patients of DLBCL. Conclusion: BOR rate at cycle 3, cycle 6, and end of the study lies within the prespecified limit for noninferiority which concludes that test product is therapeutically noninferior to reference medicinal product.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2018;volume=39;issue=3;spage=316;epage=320;aulast=AdvaniDiffuse large B-cell lymphomanon-Hodgkin's lymphomarituximab |
| spellingShingle | Suresh Advani Ghanashyam Biswas Shubhadeep Sinha Neetu Naidu Rayala Sreenivasa Chary Pankaj Thakur Anushrita Santanu Tripathi Vamsi Krishna Bandi A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (Rituximab, Roche) in Indian patients of non-hodgkin's lymphoma (HERILY) Indian Journal of Medical and Paediatric Oncology Diffuse large B-cell lymphoma non-Hodgkin's lymphoma rituximab |
| title | A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (Rituximab, Roche) in Indian patients of non-hodgkin's lymphoma (HERILY) |
| title_full | A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (Rituximab, Roche) in Indian patients of non-hodgkin's lymphoma (HERILY) |
| title_fullStr | A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (Rituximab, Roche) in Indian patients of non-hodgkin's lymphoma (HERILY) |
| title_full_unstemmed | A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (Rituximab, Roche) in Indian patients of non-hodgkin's lymphoma (HERILY) |
| title_short | A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (Rituximab, Roche) in Indian patients of non-hodgkin's lymphoma (HERILY) |
| title_sort | randomized multiple dose multicenter comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab hetero and reference medicinal product rituximab roche in indian patients of non hodgkin s lymphoma herily |
| topic | Diffuse large B-cell lymphoma non-Hodgkin's lymphoma rituximab |
| url | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2018;volume=39;issue=3;spage=316;epage=320;aulast=Advani |
| work_keys_str_mv | AT sureshadvani arandomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT ghanashyambiswas arandomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT shubhadeepsinha arandomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT neetunaidurayala arandomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT sreenivasachary arandomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT pankajthakur arandomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT anushrita arandomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT santanutripathi arandomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT vamsikrishnabandi arandomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT sureshadvani randomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT ghanashyambiswas randomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT shubhadeepsinha randomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT neetunaidurayala randomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT sreenivasachary randomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT pankajthakur randomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT anushrita randomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT santanutripathi randomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily AT vamsikrishnabandi randomizedmultipledosemulticentercomparativeparallelstudytoevaluatethesafetyandefficacyofintravenousinfusionofrituximabheteroandreferencemedicinalproductrituximabrocheinindianpatientsofnonhodgkinslymphomaherily |